DelveInsight's "ROZLYTREK Market Size, Forecast, and Market Insight Report" highlights the details around ROZLYTREK, an ...

As biomarker testing and the demand for tumor-agnostic therapies rise, ROZLYTREK can potentially target a specialized yet valuable market segment. While competition from other TRK inhibitors ...

EMA committee recommends approval of AstraZeneca’s Imfinzi in combo with chemotherapy to treat resectable non-small cell lung cancer ...

The agreement was signed in a letter of intent March 3 to set the groundwork for whether government health programs in ...

Orbis Medicines, a leader in oral macrocycle drug discovery, today announces the appointment of Mikael Dolsten, M.D., Ph.D., former Chief Scientific O ...

AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the European Union (EU) for the treatment of adults with resectable non-small cell lung cancer ...

IBC is a rare, aggressive breast cancer with higher rates in younger women and those of African descent, requiring a ...

Investment analysts at HC Wainwright reduced their Q1 2025 earnings per share estimates for Nuvalent in a report released on ...

HC Wainwright reiterated their buy rating on shares of Nuvalent (NASDAQ:NUVL – Free Report) in a report released on Monday,Benzinga reports. HC Wainwright currently has a $110.00 price objective on ...